



PreveCeutical Medical Inc.
CSE:PREV | OTC:PRVCF | FSE:18H



BIOGENE THERAPEUTICS

Q1 - 2025

Investor Presentation

Our Mission

BioGene commits to

Delivering the Future of Genetic Medicines

with Precision Delivery, opening the door to alternative patient-friendly routes of LNP administration through innovative products and platforms that target key tissues of interest in obesity and diabetes... and beyond!

DISCLAIMER

This presentation and its appendices (together, the "Presentation") have been prepared and delivered by BioGene Therapeutics Inc. ("BioGene Therapeutics" or the "Company"). The Presentation is strictly confidential and may not be reproduced or redistributed, in whole or in part, to any other person than the intended recipient without the Company's prior written consent. The Presentation is prepared for discussion and informational purposes only. The Presentation does not constitute, and should not be construed as, any offer or invitation or recommendation to buy or sell any of the securities issued by the Company and does and will not constitute or form or be part of any offering material. The Presentation contains information which has been sourced from third parties believed to be reliable, but without independent verification by the Company, its board of directors, management, employees, consultants, agents or affiliates. The Presentation contains certain forward-looking statements relating to the potential business, financial performance and results of the Company and/or industries and markets in which it is or may operate within. These statements may contain words such as "will", "expects", "anticipates", "believes", "estimates" and words of similar import. Those forward statements include: that the Company is delivering the future of generic medicines, that the Company will deliver innovative products and platforms that target key issues of interest in obesity, diabetes and beyond, that the Company or its subsidiary will obtain cash-back or any grants from the Australian government, that the Company's products (including its Sol-Gen delivery platform and its Smart-siRNAs) will be an effective method to be used in the treatment of obesity, diabetes and other nongenetic and genetic diseases, that the Company will complete its preclinical studies and enter into partnerships and agreements for clinical studies on the time anticipated by the Company, that the Company will enter into any licensing arrangements for its products, and that the Company will list its shares on Nasdaq. The assumptions made by the Company include, without limitation, that it will have access to the required qualified and experienced personnel to conduct its preclinical and clinical studies, that it will have enough capital to conduct its preclinical and clinical studies and in order to fund its operations for the duration, that its technology will achieve the predicted results, that the Company will be able to satisfy the initial listing requirements for a listing of its shares on Nasdaq, including enough capital to fund its ongoing operations for the required period and that the Company will obtain all necessary regulatory permits and consents to conduct its operations. Any forward-looking statements and other information contained in this Presentation, including assumptions, opinions, forecasts and views, including those cited from third party sources, are solely opinions and forecasts which are subject to risks, uncertainties and other factors that may cause actual events to differ materially from any anticipated development, including risks that the Company's products may not perform as, or have the benefits, expected; risks that the Company's products may not be accepted and adopted by the public; risks that the Company will not obtain FDA or other approvals as anticipated or at all; the risk that there will be delays commencing any preclinical or clinical programs as anticipated or at all; the risk that the Company will receive negative results from the Company's preclinical or clinical trials; the effects of government regulation on the Company's business; risks associated with the Company obtaining all necessary regulatory approvals for its various preclinical and clinical programs or for its products; risks associated with the Company's ability to obtain and protect rights to its intellectual property; risks and uncertainties associated with the Company's ability to raise additional capital; and other factors beyond the Company's control.

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for the Company or its management to predict all of such factors and to assess in advance the impact of such factors on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein.

This Presentation has not been reviewed or registered with any public authority, stock exchange or regulated market-place. By attending/reviewing/reading or receiving this Presentation you acknowledge that you will be solely responsible for your own assessment of the information herein, and the market and the market position of the Company and that you will conduct your own due diligence and analysis and be solely responsible for forming your own view of the potential future performance of the Company or any potential investment in the Company. Neither the Company, its management or board of directors, nor any subsidiary of the Company or any such person's board of directors, management or affiliates makes any undertaking, representation or warranty (express or implied) as to the accuracy or completeness of the information (whether written or oral and whether or not included in this Presentation including related to any materials referred to or otherwise incorporated by reference herein) concerning the matters described herein. Neither the Company nor any subsidiary of the Company or any such person's board of directors, management, employees, consultants, agents, or affiliates accepts any liability whatsoever as to any errors, omissions or misstatements contained herein and, accordingly, neither the Company nor any subsidiary of the Company or any such person's affiliates, agents, officers, directors, employees, and consultants accepts any liability whatsoever arising directly or indirectly from the use of this Presentation or the information included herein. The Presentation speaks and reflects prevailing conditions and views as of the date denoted on the cover page. It may be subject to corrections and change at any time without notice.

Board of Directors



Stephen Van Deventer

Stephen is the **Chairman, CEO and President** of BioGene Therapeutics and **PreveCeutical Medical**, with extensive experience in capital markets with a focus on life sciences. Stephen has started and raised millions in the capital markets space.



Deepak Sampath, PhD

Deepak will serve as an Independent Director for BioGene. He is the Senior VP, Head of Research at **Ultragenyx**, with previous experience at **Pfizer** and **Genetech**, along with over 100 publications, 20 issued patents and numerous IND, NDA, BLA filings and drug approvals for the treatment of cancer.



Steve Glover

Steve joins BioGene as a Board Member, bringing multifaceted experience in Fortune 100 and start-up environments. He sits as Chairman and CEO of Nasdaq-listed **ZyVersa Therapeutics** and was former Chairman of **Ambrx**, which was acquired for \$2B.



Dr. Linnéa Olofsson, PhD

Linnéa has been as a Board Member at BioGene Therapeutics and sits on the board at **PreveCeutical Medical**. Linnéa is an accomplished biophysicist with years of experience with expertise in pharmacology, oncology, cell biology and gene editing.



Patroski J. Lawson, MSP

Patroski is the founder and CEO of **KPM Group DC**, a strategic public affairs firm. With over 20 years of experience in government affairs, he has worked across local, state, federal, and global levels, including roles at **Solvay Pharmaceuticals**, **Abbott**, and **Lundbeck**.

Senior Management



Stephen Van Deventer

Stephen is the **Chairman, CEO and President** of BioGene Therapeutics and **PreveCeutical Medical**, with extensive experience in capital markets with a focus on life sciences. Stephen has started and raised millions in the capital markets space.



Alex McAuly, CPA

Alex serves as the **Chief Financial Officer** for BioGene. He is a Chartered Professional Accountant of Canada with vast experience in running publically traded companies through his astute knowledge of accounting principles in North America and Europe



Harry Parekh, PhD

Harry is welcomed to the BioGene team as **Chief Science Officer & Scientific Founder of BioGene**. Harry is currently a Director of Research and Research Group Leader at the **University of Queensland, Australia**. He also serves as **CRO & Scientific Founder** for PreveCeutical Medical.



Dr. Linnéa Olofsson, PhD

Linnéa has been appointed **Director of Science** at BioGene Therapeutics and sits on the board at **PreveCeutical Medical**. Linnéa is an accomplished biophysicist with years of experience with expertise in pharmacology, oncology, cell biology and gene editing.



Louis Lapointe

Louis will be heading **Business Development** for BioGene bringing decades of experience and execution. He will lead the team in discovering revenue generating business channels and key strategic partnerships.

Scientific and Corporate Advisory Board



Prof. Mirela Delibegović

As a member of BioGene's **Scientific Advisory Board**, Mirela brings a wealth of knowledge in metabolic physiology with a focus on diabetes, obesity and CVD. Prof Mirela holds the prestigious **Regius Chair of Physiology at The University of Aberdeen, UK.**



Barry Ticho, MD, PhD

Barry will serve on BioGene's **Scientific Advisory Board**. Barry holds several prestigious roles as Founder and Board Member at **Verve Therapeutics, Cardior Pharmaceuticals, Sania Therapeutics and Stoke Therapeutics.**



Mariya Georgieva, PhD

Mariya will serve on BioGene's **Scientific Advisory Board**. Over the past 5 years, Mariya has worked with **AstraZeneca**, as a Director of Alliances in the Diagnostic Precision Medicine division. She is adept in molecular biology, super-resolution microscopy and relationship development.



Brian Gallagher, Jr.

Brian will sit on the **Corporate Advisory Board** bringing critical investment experience within the life sciences sector raising capital through various channels including the **Michigan Biomedical Venture Fund, Slate Bio and Trek Ventures.**



Kathy Rokita

Kathy is joining the **Corporate Advisory Board** and currently is a Managing Director at **CBIZ** and has provided consulting services for physician groups and healthcare organizations for over 30 years. She has had successful exits, most notably as a Principal at Somerset CPAs.

BIOGENE AUSTRALIA

BioGene has established a wholly-owned subsidiary in Brisbane, Queensland, Australia, to bolster their research and development interests and provide significant cash-back R&D grants from the Australian government.

Brisbane hosts a series of globally-renowned research, manufacturing and clinical trial facilities.

BioGene to receive **43.5%** cash back from Australian Federal Government on all R&D, clinical trial and operational costs.



R&D Formulation & Preclinical Facility



GMP Manufacturing Facility



Queensland Government
Royal Brisbane and Women's Hospital
Metro North Health



Queensland Government
Children's Health Queensland
biogenetherapeutics.com



Queensland Government
Metro South Health

A Global Epidemic



1

OBESITY

Cases have tripled in the past decade leading to elevated risk of mortality: heart disease, stroke and dementia.

2

DIABETES

1 in 10 adults are diagnosed with diabetes. Childhood rates of diabetes & obesity are on a steep upward trajectory.


3

DRUG SIDE EFFECTS

Debilitating and even life-threatening side effects have emerged with current marketed weight-loss treatments.

Obesity Rates

Obesity Cases Triple in a Decade





- The World Obesity Federation (WOF) predicts that despite current treatments the economic impact of obesity will reach >\$4 trillion annually by 2035.
- WOF report predicts that by 2035, >**HALF** of the world's population (>>4 billion people!), will be classified as "obese".
- Childhood obesity cases are anticipated to impact >200 million boys and >170 million girls by 2035.

www.mordorintelligence.com/industry-reports/weight-loss-diabetes-drug-market

Diabetes Rates

1 in 8 Adults are Diabetic and Children Rates Rapidly Rise




- Leads to >4 million adult deaths a year.
- Over 570 million adults aged between 20 and 79 years are **currently** living with diabetes.
- Projections indicate >640 million cases by 2030, increasing by over 20% to >780 million by 2045.
- Childhood rates of diabetes continue to rise at alarming rates!

<https://www.diabetesdefa.org/assets/image/global-diabetes-epidemic-projected-growth-cases-2030-and-2045>; <https://diabetesatlas.org/data/en/>; <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101827/>

Weight Loss Drug Market

\$200Bn in the Next Decade

- The weight loss drug market was *circa.* US\$34 billion in 2024.
- Expected to surpass US\$43 billion by 2029 (CAGR >5.5%, 2024-29)
- Barclays capital markets projects a US\$200 billion market by *circa.* 2030.




<https://www.mordorintelligence.com/industry-reports/weight-loss-diabetes-drug-market> <https://www.cnbc.com/2023/04/28/obesity-drugs-to-be-worth-200-billion-in-next-10-years-barclays-says.html>

GLP1 agonists have changed the obesity treatment paradigm but **unmet medical needs remain high**

Present with an array of issues:

- Severe sometimes **life-threatening side effects**
 - **40% of patients stop treatment** by one year
- **20-40% muscle loss**
- Patients build **tolerance** over time
- **Doesn't restore metabolic functions**
 - Rebound or on it for life (if tolerated...)
- Injections are painful, **inconvenient**
- Oral route – real world challenges w.r.t dosing and bioavailability due to poor diet of target population



BioGene's solution

Dual Gene Therapy siRNAs targeting obesity and diabetes -> **restore metabolic functions with reduced side effects, increased compliance and cost-effectiveness**

SOL-GEL PLATFORM

A versatile platform revolutionizing Nose-to-Brain (N2B) delivery of therapeutics with global patents pending



BIORESPONSIVE LNP PLATFORM

Bioresponsive self-assembling lipid nanoparticle (bLNP) platform technology effectively delivering and releasing genetic cargo

US Patent GRANTED



Smart-siRNAs

Metabolically-stabilised and multiple exon targeting siRNAs specifically against PTP1B, validated



DUAL GENE THERAPY

Smart-siRNAs targeting PTP1B delivered using our bLNP platform directly N2B with Sol-Gel, in an easy to use nasal spray format

SOL-GEL Nose To Brain Platform Delivery



Challenges with Oral Delivery Route

Rapid breakdown by enzymes in the gut. Increasing incidence of GI distress from oral dosing of medication complicated by poor diet. Low bioavailability.




Direct Nose-to-Brain Delivery

Desired patient outcomes are achieved by consistent and sustained delivery to the whole brain, dose after dose.



The Blood-Brain-Barrier

BBB remains a universal hurdle for drugs intended for the brain when administered via conventional routes (oral, injection), which we altogether circumvent.



Olfactory Pathway Targeting with Sol-Gel


An ideal and proven pathway for rapid, direct and sustained brain delivery of therapeutic cargo, via our patient-friendly nasal spray Sol-Gel platform.

What is the Sol-Gel Platform?


A *solution* that is engineered to rapidly *gel* upon contact with mucosa...

- Targeted spray delivery and retention on mucosa
- Controlled and sustained release (nanomicellar-formulation) to and through mucosa
- **Sol-Gel delivery altogether circumvents the BBB – not a hurdle for BioGene!**


Room temperature



Solution state permits spraying via devices and extensive/uniform tissue coverage




Body Temperature



Mucoadhesive functional gel promotes sustained & controlled delivery

SOL-GEL Platform Technology & Device


Olfactory epithelia



Conventional nasal sprays deliver formulation throughout the nasal cavity, and are rapidly cleared...

- Anterior & posterior leakage
- Rapid ciliary clearance
- Poor retention
- Unpredictable transmucosal delivery to trigeminal nerves

Olfactory epithelia



Olfactory mucosa targeting, rapid sol-to-gel transition, muco-retention and sustained delivery

- Exclusive olfactory targeting
- Direct, rapid nose-to-brain delivery
- Mucoadhesive sol-gel provides for sustained & controlled delivery
- Patient-friendly water or buffer vehicle - **no** alcohols or oils



Non-Viral Vector Platform - BioGene's Bioresponsive LNPs (bLNP)


Vectors possess a unique bioresponsive gene cargo-releasing feature:

US Patent 11,566,044 – granted 31-Mar-23

- **Efficient Delivery:** The bLNP systems possess **endosomal escape features** AND **actively releases genetic cargo** from their carrier
- **Low Toxicity:** Non-viral, self-assembling bio-inspired patented bLNPs that employ naturally-derived building blocks
- **Cost-effective:** Synthesized using robust, scalable, well-established chemistries at **high yield**

Key features of BioGene's Bioresponsive LNPs (bLNP)

- Next generation – non-viral **bioresponsive vector**
- US Patent # 11,566,044 granted, 31st March 2023



Comprehensive release of **all** genetic cargo from their carrier...


Significant implications for precision medicine in **mainstream** disease re: dosing, pricing and patient accessibility...

PTP1B Validation: Diabetes (Insulin resistance) & Obesity (leptin signaling)


PTP1B directly dephosphorylates the Insulin Receptor while indirectly acting on the leptin receptor to regulate satiety through Jak2/Stat3.

Dual approach : our bLNPs specifically targeting PTP1B has been uniquely designed with lipids with both anti-inflammatory and direct PTP1B inhibition properties

50% reduction in PTP1B deemed adequate to restore metabolic homeostasis.



Mice lacking neuronal PTP1B are resistant to diet induced obesity and are protected from developing leptin resistance



Neuronal PTP1B regulates body weight, adiposity and leptin action

Kendra K Bence^{1,4}, Mirela Delibegovic¹, Bingzhong Xue², Cem Z Gorgun³, Gokhan S Hotamisligil³, Benjamin G Neel¹ & Barbara B Kahn²

NATURE MEDICINE VOLUME 12 | NUMBER 8 | AUGUST 2006

Conclusion of the study: "for effective obesity treatment and optimal therapy for type 2 diabetes, PTP1B inhibitors **must be directed to the brain**"

Preclinical development ; downregulating PTP1B in the **CNS** only, restores both insulin & leptin sensitivity

CNS

Neuron-specific PTP1B $-/-$ leads to

- Decrease in body weight & fat mass
- Increased activity and energy expenditure
- Increased leptin secretion
- Improved glucose homeostasis.

PTP1B $-/-$ in leptin-receptor expressing neurons leads to

- Leptin hypersensitivity
- Decrease in body weight & fat mass
- Decreased body weight & fat mass gain upon HFD-feeding compared to WT

PERIPHERY

PTP1B $-/-$ in skeletal muscle leads to


- Body weight effect similar to WT
- Improved glucose insulin sensitivity

PTP1B $-/-$ in liver leads to


- No effect on body weight.
- Decreased gluconeogenesis and plasma lipid levels
- Protective against HFD-induced inflammation and ER-stress.

PTP1B $-/-$ in adipose leads to

- Potential to increased body weight, enlarge adipocytes and impair insulin sensitivity
- Protection against atherosclerosis



PTP1B is a strong drug target candidate for obesity, T2D and other therapeutic areas



PTP1B inhibition reduces neuroinflammation and fronto-temporal dementia in animal models displaying potential for the treatment of **Alzheimer**

Source: Pharmacological PTP1B inhibition rescues motor learning, neuroinflammation, and hyperglycaemia in a mouse model of Alzheimer's disease, Franklin et al, Exp Neurology, 2024

PTP1B inhibition has been demonstrated to enhance anti-tumor immunity and combat **solid-state cancer**


Source: A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity, Liang et al, Nat Comm, 2023

Ongoing clinical trials:

- PTP1B Implication in the Vascular Dysfunction Associated With **Obstructive Sleep Apnea**, Angers, France (NCT04235023)
- Correlation Between PTP1B Expression and **Organ Failure During Sepsis**, Univ Hospital Rouen, France (NCT03189355)
- MSI1436 – PTP1B inhibitor for **metastatic breast cancer**

PTPN1 Gene Targeting Strategy with BioGene's Smart-siRNAs

PTPN1 gene comprises 10 exons, each potential targets for siRNA:



01.

Successfully engineered selective, potent siRNAs independently targeting multiple exons of *PTPN1*

02.

siRNAs against both mouse and human variants of distinct exons were engineered in parallel, paving the way for PoC preclinical and clinical studies



03.

siRNAs sequences were engineered to be biostable ('Smart-siRNAs'), and novel w.r.t the prior art/published sequences

Adv Cancer Res. 2021 ; 152: 263–303. doi:10.1016/bs.acr.2021.06.001; Acc Chem Res. 2017 January 17; 50(1): 122–129. doi:10.1021/acs.accounts.6b00537

Potent Gene Silencing Confirmed Using BioGene's Bioresponsive LNPs (bLNPs)

- bLNPs possess the unique bioresponsive 'gene-releasing' linker (US Patent #11,566,044 – granted 31/Mar/23)
- UQP12 & UQP15 (top and bottom graphs) represent select Smart-siRNAs showing potent gene silencing when formulated with two distinct bLNPs.
- UQP12 & UQP15 represent only two uniquely designed metabolically-stablized siRNAs from our extensive library that display potent gene & protein silencing.




Planned Diabetes and Obesity Preclinical Study

The study will evaluate BioGene's Smart-siRNAs versus conventional constructs using bioresponsive LNP formulations in rodent models of diabetes and obesity.

The study design includes mice cohorts for robust statistical analysis, appropriate control groups, and comparison of administration routes.

- 01 Location: The University of Queensland, Brisbane
→ Extensive expertise with Sol-Gel engineering, bLNP formulation & preclinical models of obesity and diabetes
- 02 Research Team Led by BioGene's Chief Research Officer & Scientific Founder, Dr. Harry Parekh.
- 03 Objectives: Assess weight changes, PTP-1B levels in major tissues, tissue histology, and classical blood and urine biomarkers (e.g. glucose, triglycerides) throughout the extended treatment period.
- 04 Success Criteria: Weight reduction; Restoration of glucose levels/insulin sensitivity, increased activity, and improved behavioral patterns in diabetic and obese mice.

Timeline



BioGene's solution

Dual Gene Therapy siRNAs targeting obesity and diabetes -> **restore metabolic functions with reduced side effects, increased compliance and cost-effectiveness**

SOL-GEL PLATFORM

A versatile platform revolutionizing Nose-to-Brain delivery of therapeutics with global patents pending



BIORESPONSIVE LNP PLATFORM

Bioresponsive self-assembling lipid nanoparticle (bLNP) platform technology effectively delivering and releasing genetic cargo

US Patent GRANTED



Smart-siRNAs

Metabolically-stabilised and multiple exon targeting siRNAs specifically against PTP1B, validated



DUAL GENE THERAPY

Smart-siRNAs targeting PTP1B delivered using our bLNP platform directly N2B with Sol-Gel, in an easy to use nasal spray format

Accessing non-dilutive funding from the Australian Medical Research Future Fund (MRFF) grant scheme


- The Medical Research Future Fund (MRFF) is a **\$20 billion** long-term investment supporting Australian health and medical research
- The MRFF aims to transform health and medical research and innovation to improve lives, build the economy and contribute to health system sustainability
- MRFF grant applicants are encouraged to have industry support (cash & in-kind)....

'Research Translation' is one of 4 main priority themes:

- Examples grant call typically for preclinical-thru-clinical trials
- Funding of innovation programs that deliver a '**moonshot**' by creating a treatment for a currently serious and incurable health condition, through a series of linked projects
- Develop novel health technologies and/or re-purpose existing health technologies in a novel way - **BioGene is a perfect fit!**
- Max funding per application: **AUD 25 million for up to 5 years**

<https://www.health.gov.au/our-work/medical-research-future-fund/mrff-research-themes>

The Landscape is Rapidly Evolving to Next Generation Therapies



Revenue and Corporate Strategy



Platform
Licensing
Potential



Acquisition and
Partnerships




Direct Listing
on NASDAQ

Global Collaborators



Thank You



PreveCeutical Medical Inc.
CSE:PREV | OTC:PRVCF | FSE:18H

Contact Page



ir@biogenetherapeutics.com



biogenetherapeutics.com

Source

CHEMICAL REVIEWS Review
pubs.acs.org/CR

Type 2 Diabetes Mellitus: Limitations of Conventional Therapies and Intervention with Nucleic Acid-Based Therapeutics

Ganesh R. Kokil,[†] Rakesh N. Veedu,^{*,‡,§,||} Grant A. Ramm,^{1,¶} Johannes B. Prins,[∇] and Harendra S. Parekh^{*,†}

Research Article Journal of Peptide Science
Received: 12 October 2010 | Revised: 24 November 2010 | Accepted: 1 December 2010 | Published online in Wiley Online Library: (wileyonlinelibrary.com) DOI 10.1002/psc.1347

Low-generation asymmetric dendrimers exhibit minimal toxicity and effectively complex DNA

Neha Shah,^{a,b} Raymond J. Steptoe^{b*} and Harendra S. Parekh^{a*}

J. Phys. Chem. B **2010**, *114*, 9231–9237

Structure and Dynamics of Multiple Cationic Vectors–siRNA Complexation by All-Atom Molecular Dynamics Simulations

Defang Ouyang,^{†,‡} Hong Zhang,[‡] Harendra S. Parekh,^{*,†} and Sean C. Smith^{*,‡}

School of Pharmacy and Centre for Computational Molecular Science, Australian Institute of Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD 4072, Australia

Received: December 17, 2009; Revised Manuscript Received: June 1, 2010

Advanced Drug Delivery Reviews
Available online 8 January 2015
In Press, Corrected Proof — Note to users

Are caveolae a cellular entry route for non-viral therapeutic delivery systems? *

Prarthana V. Rewatkar^a, Robert G. Parton^b, Harendra S. Parekh^a, Marie-Odile Parat^a

Journal of Peptide Science EPS
The official Journal of the European Peptide Society

Research Article | Full Access

Low-generation asymmetric dendrimers exhibit minimal toxicity and effectively complex DNA

Neha Shah, Raymond J. Steptoe, Harendra S. Parekh

First published: 24 February 2011 | <https://doi.org/10.1002/psc.1347> | Citations: 46

Pharm Res (2014) 31:3150–3160
DOI 10.1007/s11095-014-1408-1

RESEARCH ARTICLE

Asymmetric Peptide Dendrimers are Effective for Antibody-Mediated Delivery of Diverse Payloads to in Vitro and in Vivo

SCIENTIFIC REPORTS

OPEN **Self-assembling asymmetric peptide-dendrimer micelles – a platform for effective and versatile *in vitro* nucleic acid delivery**

Received: 29 August 2017
Accepted: 12 February 2018
Published online: 19 March 2018

Ganesh R. Kokil¹, Rakesh N. Veedu^{2,3,4}, Bao Tri Le^{2,3}, Grant A. Ramm^{5,6} & Harendra S. Parekh¹

ADVANCED THEORY AND SIMULATIONS

Full Paper | Full Access

Cell Membrane Penetration without Pore Formation: Chameleonic Properties of Dendrimers in Response to Hydrophobic and Hydrophilic Environments

Sergio de Luca, Prasenjit Seal, Harendra S. Parekh, Karnaker R. Tupally, Sean C. Smith

First published: 03 June 2020 | <https://doi.org/10.1002/adts.201900152>

ACS Biomaterials Article
SCIENCE & ENGINEERING
pubs.acs.org/journal/abseba

Express in Vitro Plasmid Transfection Achieved with 16⁺ Asymmetric Peptide Dendrimers

Prarthana V. Rewatkar,[†] David P. Sester,[‡] Harendra S. Parekh,^{*,†} and Marie-Odile Parat^{*,†}

[†]School of Pharmacy, The University of Queensland, 20 Cornwall Street, Woolloongabba, Queensland 4102, Australia
[‡]School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Queensland 4072, Australia

[Supporting Information](#)

Sources

1. <https://www.mayoclinic.org/drugs-supplements/semaglutide-subcutaneous-route/side-effects/drg-20406730?p=1>

1. [cnbc.com](https://www.cnbc.com) - Obesity drug industry could be worth \$200 billion within the decade, says Barclays

1. [news.harvard.edu](https://www.news.harvard.edu) - Are new weight-loss drugs the answer to America's obesity problem?

1. [zs.com](https://www.zs.com) - Pharma needs a commercial model that can solve it

1. [msn.com](https://www.msn.com) - Obesity drug industry could be worth \$200 billion within the decade, says Barclays